HK1040055B - 奥氮平和氟西汀在制备治疗对抗治疗的严重抑郁症的药物中的应用 - Google Patents

奥氮平和氟西汀在制备治疗对抗治疗的严重抑郁症的药物中的应用 Download PDF

Info

Publication number
HK1040055B
HK1040055B HK02101563.3A HK02101563A HK1040055B HK 1040055 B HK1040055 B HK 1040055B HK 02101563 A HK02101563 A HK 02101563A HK 1040055 B HK1040055 B HK 1040055B
Authority
HK
Hong Kong
Prior art keywords
treatment
olanzapine
fluoxetine
depression
compound
Prior art date
Application number
HK02101563.3A
Other languages
English (en)
Chinese (zh)
Other versions
HK1040055A1 (en
Inventor
G‧D‧托勒夫森
Original Assignee
伊莱利利公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 伊莱利利公司 filed Critical 伊莱利利公司
Publication of HK1040055A1 publication Critical patent/HK1040055A1/xx
Publication of HK1040055B publication Critical patent/HK1040055B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compositions Of Oxide Ceramics (AREA)
HK02101563.3A 1998-05-22 1999-05-21 奥氮平和氟西汀在制备治疗对抗治疗的严重抑郁症的药物中的应用 HK1040055B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8644498P 1998-05-22 1998-05-22
US60/086444 1998-05-22
PCT/US1999/011276 WO1999061027A1 (en) 1998-05-22 1999-05-21 Combination therapy for treatment of refractory depression

Publications (2)

Publication Number Publication Date
HK1040055A1 HK1040055A1 (en) 2002-05-24
HK1040055B true HK1040055B (zh) 2005-04-01

Family

ID=22198612

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02101563.3A HK1040055B (zh) 1998-05-22 1999-05-21 奥氮平和氟西汀在制备治疗对抗治疗的严重抑郁症的药物中的应用

Country Status (24)

Country Link
EP (1) EP0958824A3 (https=)
JP (1) JP2002516282A (https=)
KR (1) KR20010043730A (https=)
CN (1) CN1154496C (https=)
AU (1) AU761510B2 (https=)
BR (1) BR9911049A (https=)
CA (1) CA2332814C (https=)
CZ (1) CZ20004279A3 (https=)
EA (1) EA004539B1 (https=)
HK (1) HK1040055B (https=)
HR (1) HRP20000797A2 (https=)
HU (1) HUP0101901A3 (https=)
ID (1) ID26861A (https=)
IL (1) IL139592A (https=)
MY (1) MY127938A (https=)
NO (1) NO20005885L (https=)
NZ (1) NZ507980A (https=)
PL (1) PL344331A1 (https=)
SK (1) SK17512000A3 (https=)
TR (1) TR200003443T2 (https=)
TW (1) TWI226829B (https=)
UA (1) UA78181C2 (https=)
WO (1) WO1999061027A1 (https=)
ZA (1) ZA200006815B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174882B1 (en) * 1998-11-23 2001-01-16 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
SI1237553T1 (sl) * 1999-12-06 2006-06-30 Lundbeck & Co As H Kombinacija inhibitorja ponovnega navzema serotonina in antagonista 5-ht 2c?, inverznega agonista ali delnega agonista
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
JP2004517112A (ja) * 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション
AU2003268026A1 (en) 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
GB0229583D0 (en) * 2002-12-19 2003-01-22 Cipla Ltd A process for preparing duloxetine and intermediates for use therein
CN1989968B (zh) 2002-12-27 2011-05-11 大塚制药株式会社 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
AU2004269858A1 (en) * 2003-09-04 2005-03-17 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and Loxapine
SI1668014T1 (sl) 2003-09-17 2009-06-30 Janssen Pharmaceutica Nv Kondenzirane heterociklične spojine kot modulatorji serotoninskih receptorjev
WO2005053703A1 (en) 2003-12-02 2005-06-16 Leslie James Sheldon Combination therapy for dementia, depression and apathy
EP1696896A2 (en) * 2003-12-15 2006-09-06 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP1928437A2 (en) * 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2044043B2 (en) 2006-06-16 2021-03-03 H. Lundbeck A/S 1- ý[- (2, 4-dimethylphenylsulfanyl) -phenyl]piperazine hydrobromide as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
PL2120878T3 (pl) * 2007-02-09 2015-01-30 Alphapharm Pty Ltd Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN105769875A (zh) * 2014-12-22 2016-07-20 扬子江药业集团上海海尼药业有限公司 复方奥氮平盐酸氟西汀胶囊的制备方法
CN108938645A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种抗精神病药物组合物
CN111084778B (zh) * 2019-12-31 2022-06-24 北京鑫开元医药科技有限公司 一种奥氮平盐酸氟西汀胶囊及其制备方法
CN114569566A (zh) * 2020-12-02 2022-06-03 四川科瑞德制药股份有限公司 一种盐酸米那普仑制剂的制备方法
ES3054324A1 (es) * 2024-07-12 2026-02-02 Univ Malaga Galanina (1-15) y Fluoxetina en el tratamiento de la depresión resistente al tratamiento

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8072691A (en) * 1990-06-28 1992-01-23 Beecham Group Plc Pharmaceutical preparations
FR2716680B1 (fr) * 1994-02-25 1996-04-05 Adir Nouveaux dérivés de benzodioxane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
WO1997033577A1 (en) * 1996-03-11 1997-09-18 Eli Lilly And Company Method for treating bipolar disorder
WO1997035586A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Also Published As

Publication number Publication date
EA200001218A1 (ru) 2001-06-25
IL139592A0 (en) 2002-02-10
HK1040055A1 (en) 2002-05-24
HUP0101901A3 (en) 2002-06-28
IL139592A (en) 2005-08-31
CN1154496C (zh) 2004-06-23
EP0958824A2 (en) 1999-11-24
NO20005885D0 (no) 2000-11-21
WO1999061027A1 (en) 1999-12-02
SK17512000A3 (sk) 2002-02-05
EA004539B1 (ru) 2004-06-24
AU761510B2 (en) 2003-06-05
CA2332814C (en) 2008-11-04
JP2002516282A (ja) 2002-06-04
KR20010043730A (ko) 2001-05-25
AU4008699A (en) 1999-12-13
CZ20004279A3 (cs) 2001-09-12
CN1311681A (zh) 2001-09-05
PL344331A1 (en) 2001-11-05
NZ507980A (en) 2003-10-31
UA78181C2 (en) 2007-03-15
HRP20000797A2 (en) 2001-10-31
BR9911049A (pt) 2001-02-06
EP0958824A3 (en) 1999-12-01
MY127938A (en) 2007-01-31
ZA200006815B (en) 2002-01-14
CA2332814A1 (en) 1999-12-02
NO20005885L (no) 2001-01-17
TR200003443T2 (tr) 2001-03-21
HUP0101901A2 (hu) 2001-11-28
TWI226829B (en) 2005-01-21
ID26861A (id) 2001-02-15

Similar Documents

Publication Publication Date Title
CN1162156C (zh) 奥氮平与氟西汀在制备治疗精神病药物中的用途
HK1040055A1 (en) Use of olanzapine and fluoxetine in the preparation of a medicament for the treatment of treatment resistant major depression
CN1302207A (zh) 双相性精神障碍的联合治疗
CN1146567C (zh) 奥氮平二水合物d
CN1036652C (zh) 碱式季酰胺，其制备方法及其药物组合物
CN1805938A (zh) 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
CN1214043A (zh) 苄基(亚苄基)-内酰胺衍生物,它们的制备以及作为5-ht1a和/或5-ht1d受体的选择性拮抗剂(激动剂)的用途
CN1113436A (zh) 药物反应的增效作用
CN1163484C (zh) 4-芳酰基-哌啶-ccr-3受体拮抗剂ⅲ
CN1366881A (zh) 用雌激素激动剂/拮抗剂治疗某些癌症的方法
CN1361783A (zh) 噻唑并衍生物和含有它们的药物组合物
CN1195519C (zh) 5－HT再摄取抑制剂与h5－HT1B拮抗剂或部分激动剂的组合物
CN1494422A (zh) Gabaa反相激动剂与烟碱受体不完全激动剂、雌激素、选择性雌激素调节剂、或维生素e联合用于认知障碍的用途
CN1148340A (zh) 治疗与5htzb受体有关病症的方法
CN1468224A (zh) 用作α-2拮抗剂的喹啉衍生物
CN1117092C (zh) 氮杂双环化合物,其药物组合物及医药用途
CN1545513A (zh) 新颖的2h-哒嗪-3-酮衍生物、含有它们的药物组合物和活性成分的制备方法
CN1431997A (zh) 2－酰基吲哚衍生物及它们作为抗肿瘤剂的用途
CN1111986A (zh) 治疗肠应激综合症的异噁唑衍生物
CN1382440A (zh) 用于治疗抑郁症或预防认知功能退化的方法和药盒
CN1268949A (zh) 稠合噻吩化合物及其医药用途
CN1278727A (zh) 单胺氧化酶抑制剂和h5－ht1B拮抗剂或部分激动剂的组合
CN1662544A (zh) 对血清素受体具有亲和力、可用作治疗剂的新型四环芳基磺酰吲哚、其制备方法及其药物组合物
CN1332740A (zh) 用于抗抑郁疗法的5－ht1拮抗剂
CN1639124A (zh) 作为毒蕈碱受体拮抗剂的氨基四氢萘衍生物

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110521